drugset / Trial / NCT05362786
Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Chronic Kidney Disease
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and tolerability of intravenously delivered mesenchymal steml cells (MSC) in one of two fixed dosing regimens at two time points in patients with chronic kidney disease.
Timeline
- Start
- 2022-07-01
- Primary completion
- 2024-07-24
- Completion
- 2024-07-24
Publications
- Patel HA, Wang J, Zinn CJ, Learmonth M, Lerman LO, Wolfram J, Hickson LJ. Fortifying the Diabetic Kidney Disease Treatment Armamentarium: Multitarget Senotherapeutic and Regenerative Strategies. J Am Soc Nephrol. 2025 May 7;36(8):1655-1658. doi: 10.1681/ASN.0000000754. No abstract available.
- Andrews TD, Day GS, Irani SR, Kanekiyo T, Hickson LJ. Uremic Toxins, CKD, and Cognitive Dysfunction. J Am Soc Nephrol. 2025 Jun 1;36(6):1208-1226. doi: 10.1681/ASN.0000000675. Epub 2025 Feb 26.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Allogeneic adipose-derived mesenchymal stem cells (MSC) | Cell therapy | 100 cells | Intravenous |
| Subject | Allogeneic adipose-derived mesenchymal stem cells (MSC) | Cell therapy | 200 cells | Intravenous |